Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial
June 09, 2020 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- Amphastar® Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has...
Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
June 02, 2020 16:05 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO and Dan Dischner, Vice President of Corporate...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2020
May 07, 2020 16:05 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31,...
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2020
May 04, 2020 06:01 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2020 ended March...
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial
April 27, 2020 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has...
Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure
April 13, 2020 17:16 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a California-based, specialty, generic pharmaceutical...
Amphastar Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference
April 09, 2020 06:01 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, April 09, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 19th...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2019
March 12, 2020 16:05 ET
|
Amphastar Pharmaceuticals, Inc.
Reports Net Revenues of $83.4 Million for the Three Months Ended December 31, 2019 RANCHO CUCAMONGA, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)...
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12th, 2020
March 05, 2020 16:05 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2019 ended...
Amphastar Pharmaceuticals Receives FDA Approval for Supplement to its Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP 8.4%, 50mEq/50mL
February 27, 2020 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (“FDA”) granted approval of its...